**AlcHepNet Observational Study Eligibility and Enrollment**

* **Alcoholic Hepatitis Definition**
  + The diagnosis of Alcoholic Hepatitis will be established based on:
  + Average daily ethanol consumption of > 40 grams/day for women and > 60 grams/day for men for a minimum of 6 months and within the 4 weeks prior to study enrollment. Judgment regarding daily and yearly alcohol use will be made by the site investigator
  + Clinical evaluation and appropriate laboratory testing as defined by a total bilirubin > 3 mg/dL and AST > 50 U/L.
  + If the diagnosis of AH remains in question, a liver biopsy will be required (if clinically feasible and no contra-indications).
* **Inclusion and Exclusion Criteria**
  + **Controls: Heavy drinkers without alcoholic hepatitis**
    - **Inclusion criteria**
      * History of chronic alcohol consumption sufficient to cause liver damage. Generally, this is considered to be >40 g/day for women and >60 g/day for men, for many years (usually decades). Judgement about chronic alcohol consumption will be made by the site investigator.
      * *Note: 1 standard drink = 14 g of alcohol, which is equivalent to the amount of alcohol contained in a 12 oz. can of beer, 5 oz. glass of wine , 8 oz. glass of malt liquor or 1.5 oz. shot of 80 proof spirits)*
      * Ability to understand and willingness to provide written consent.
      * Age greater or equal to 21 years
    - **Exclusion Criteria**
      * Past evidence of alcoholic liver disease, defined as a bilirubin > 2.0 mg/dL, an AST > 1.5 ULN, any hospital admission for liver disease, a Fibroscan score >7.0 kPa, or the presence of esophageal varices or ascites (at any time in the past).
      * Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, NAFLD, hepatitis C, or hepatitis B. Judgement about the significance of other liver diseases in causing liver damage will be made by the site investigator.

(NOTE: The presence of hepatitis C, hepatitis B, or HIV is not exclusion to participation.)

* + - * Alcohol intake at **less than** 40g/day for women or 60 g/day for men for longer than the past 28 days
      * If liver stiffness has been assessed within the prior 90 days, then stiffness suggesting fibrosis of F1 or greater is excluded. For Fibroscan, this is a fibrosis score >7.0 kPa.
      * Pregnant or breast feeding
      * Any of the following laboratory abnormalities within 90 days prior to signing the consent.
      * Creatinine: >1.5 mg/dL
      * Hemoglobin: <12 g/dL
      * Total bilirubin: >1.5 mg/dL1
      * AST: >40 IU/mL
      * ALT: >40 IU/mL
  + **CASES: Heavy drinkers with alcoholic hepatitis**
    - **Inclusion criteria**
      * A clinical diagnosis of alcoholic hepatitis
      * Serum total bilirubin >3 mg/dL
      * Ability to understand and willingness to provide written consent
      * Age greater or equal to 21 years
      * Re-enrollment of an alcoholic hepatitis donor is permissible up to 4 times if the donor presents with a new episode of alcoholic hepatitis 24 weeks or longer after the most recent enrollment in the study
    - **Exclusion criteria**
      * Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, NAFLD, hepatitis C, or hepatitis B. Judgement about the significance of other liver diseases in causing liver damage will be made by the site investigator.
        + (NOTE: The presence of hepatitis C, hepatitis B, or HIV is not exclusion to participation.)
      * Pregnant or breast feeding
      * Based on the judgment of the investigator, subject is not capable of understanding or complying with the study requirements.
  + **HEALTHY DONORS**
    - **Inclusion criteria**
      * AUDIT-C scores of <4 for men and <3 for women (signifying no alcohol misuse)
      * Abstinent (consumption of less than one standard drink/week) during the 6 months prior to enrollment
      * Ability to understand and willingness to provide written consent.
    - **Exclusion Criteria**
      * Clinical history or laboratory evidence of liver disease including alcoholic liver disease, NAFLD, hemochromatosis, alcoholic hepatitis, autoimmune liver disease, Wilson disease, hepatitis C, or hepatitis B.
      * Presence of diabetes (requiring treatment with oral agents or insulin), significant heart disease (prior history of heart disease, other than hypertension), or chronic lung disease (requiring chronic treatment)
      * Immune related conditions (such as Crohn’s disease, rheumatoid arthritis, ulcerative colitis, systemic lupus erythematosus, severe psoriasis, etc.)
      * Known infection with HIV
      * Presumed infection, or use of antibiotics or other medications (e.g., corticosteroids) that would affect immune function, within the past 14 days
      * BMI>32
      * Current or known history of cancer (except *in situ* carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment
      * Pregnant or breast feeding
      * Any of the following laboratory abnormalities within 90 days prior to signing the consent.
        + Creatinine: >1.5 mg/dL
        + Hemoglobin: <12 g/dL
        + Total bilirubin: >1.5 mg/dL1
        + AST: >40 IU/mL
        + ALT: >40 IU/mL
      * Based on the judgment of the investigator, subject is not capable of complying with the study requirements